Turn your advanced therapy medicinal products (ATMPs) into clinical reality with targeted technology platforms and expert CRDMO services that support you every step of the way.
Streamline your ATMP technical R&D and IND timelines with expert-led development, manufacturing, and QC services.
From early research to commercial manufacturing, we accelerate your projects with innovative technology development across CGT, mRNA-LNPs, and other ATMP modalities.
Utilize our robust CGT CDMO platforms, optimized for high quality and productivity. We specialize in plasmids, mRNA-LNP, sgRNA, viral vectors, and cell therapy products (CAR-T, CAR-NK, iPSC, MSC, TIL).
View CDMO servicesEnsure product integrity and regulatory compliance with our Analytical Development & Testing Services, harnessing state-of-the-art technologies and quality infrastructures.
View Analytical servicesSupport your discovery and preclinical studies with our production services for plasmids, mRNA-LNP, sgRNA, and viruses, including lentivirus, AAV, and adenovirus.
View CRO servicesCenters of Excellence for manufacturing and testing
GMP batches successfully delivered
INDs filed and accepted with FDA, EMA, and CDE
Centers of Excellence for manufacturing and testing
GMP batches successfully delivered
INDs filed and accepted with FDA, EMA, and CDE
Accelerate your discovery studies, GMP manufacturing, and analytical assay development with our ready-to-use cell and gene products, available in R&D and GMP grades.
With a perfect audit record from over 100 clients, our products are optimally designed for efficacy, safety, and reliability.
Fast and traceable production
Robust technical expertise and support
High-quality and tested products
Access ready-for-use GMP-grade AAV and LVV helper plasmids.
Save time on your viral vector GMP manufacturing
Discover our AAV empty capsids, available in various serotypes.
Chromatography purified
Extensively characterized AAV empty capsids
Utilize our GFP, GFP-Luciferase, and CD19-CAR lentiviral vectors for potency, efficacy, and CAR-T studies.
Chromatography purified & high transduction efficiency
Potent and tested
Discover our iPSC generation products, reprogramming cocktail, and CRISPR gene editing mRNA-LNP.
Highly efficient mRNA-LNP reprogramming cocktail
Robust in iPSC generation
Integrate our Ubrinuclease into your cell and gene therapy and biologics manufacturing processes.
GMP-grade, fully QC released
With DNA & RNA nuclease activities
Headquartered in Maryland, USA, and operating across North America and Asia, uBriGene is a global leader in ATMPs, cell and gene therapy CDMO services, and testing.
With cutting-edge GMP facilities and integrated technology platforms, we build the bridge that transforms your ATMP concepts into tomorrow’s therapies. Our expertise spans preclinical studies, IND enabling, to commercialization, ensuring seamless development at every stage.
Discover the manufacturing processes behind CAR-T cell therapies.
Learn how to accelerate the development of iPSC-derived cell therapies.
Learn how we enhance LVV productivity through cell suspension techniques.
Discover manufacturing approaches for LVV and its deployment in cell therapies.
March 12, 2024
uBriGene Biosciences announces its new Cell Therapy Potency Analytical Development and GMP Testing service, launching at the Hanson Wade Cell Therapy Potency Assay Summit in Boston, March 19-21, 2024.
Read Press ReleaseMarch 12, 2024
uBriGene (Boston) Biosciences has completed its asset purchase from Mustang Bio, acquiring a state-of-the-art manufacturing facility in Worcester, Massachusetts, enhancing its production capabilities.
Read Press ReleaseuBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies for Solid Tumors
uBriGene Supports FDA IND Clearance of Next-Generation Gene-Edited TIL Therapy GT307 Through Integrated Cell Therapy CDMO Manufacturing
